“VenatoRx Pharmaceuticals’ discovery research team has integrated KeMyth Biotech’s engineered K. pneumoniae tool strains into a diagnostic panel to provide important guidance on properties favoring improved porin entry and selectivity for this important clinical Gram-negative pathogen. We believe that it’s critical to expand our understanding about drug permeability in clinically important pathogens to drive further development of new antibiotics.” Denis Daigle, Director of Biology, VenatoRx Pharmaceuticals
“Developing new treatments effective against Gram-negative pathogens is one of the major challenges for public healthcare systems. The discovery of new antimicrobial therapies targeting these bacteria is extremely difficult because of their intrinsic resistance of these bacteria due to low permeability of the Gram-negative cell envelope combined with efficient drug efflux mechanisms. Therefore the development of tools such as the Kemyth Biotech library of genetically engineered K. pneumoniae mutants is important to facilitate research to these mechanisms. The discovery team at Antabio uses the tools developed by Kemyth Biotech as an essential part of its research and development process.” Nicolas Sprynski, Head of Discovery Biology, Antabio
“The library of genetically engineered K. pneumoniae mutants made by KeMyth Biotech represent important new tools for antibacterial research as they enable rapid insights into mechanisms of uptake and efflux in this problematic pathogen. Our research team at Entasis is currently using them routinely in our discovery efforts and is grateful that this important resource has been made available to the general community.” Alita Miller, Head of Bioscience, Entasis Therapeutics
“Antimicrobial resistance has emerged as a global health problem in recent years. KeMyth Biotech set up the K. pneumoniae resistance system and provide convenient and efficient platform to screen out the useful compounds to against the antimicrobial-resistant bacteria. Our research team use the tool developed by KeMyth Biotech to facilitate identifying compound candidates to overcome the challenge of resistance.” Carmay Lim, Distinguished Research Fellow, Institute of Biomedical Sciences, Academia Sinica
